Helix BioPharma Corp. Total Liabilities
Helix BioPharma Corp. total liabilities. Based on the latest financial reports, Helix BioPharma Corp. (HBP) has total liabilities worth CA$3.16 Million CAD (≈ $2.29 Million USD) as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Helix BioPharma Corp. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Helix BioPharma Corp. (2007–2025)
Total liabilities of Helix BioPharma Corp. from 2007 to 2025. This chart illustrates how Helix BioPharma Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore HBP long-term investment intensity to see how much of total assets are deployed in long-term investments.
Helix BioPharma Corp. Competitors by Total Liabilities
The table below lists competitors of Helix BioPharma Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cenit Co. Ltd
KQ:037760
|
Korea | ₩124.74 Billion |
|
DLH Holdings Corp
NASDAQ:DLHC
|
USA | $161.54 Million |
|
ICAPE HOLDING EO -40
F:Z8J
|
Germany | €120.45 Million |
|
Reliance Securities Tbk
JK:RELI
|
Indonesia | Rp169.08 Billion |
|
Company K Partners Limited
KQ:307930
|
Korea | ₩5.40 Billion |
|
Southport Acquisition Corp
NYSE:PORT
|
USA | $10.58 Million |
|
Broadwind Energy Inc
NASDAQ:BWEN
|
USA | $50.52 Million |
|
Harmoney Corp Ltd
AU:HMY
|
Australia | AU$908.11 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Helix BioPharma Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Helix BioPharma Corp..
Liquidity & Leverage Metrics
Helix BioPharma Corp. Total Liabilities Ratios Explained
Helix BioPharma Corp. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Helix BioPharma Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Helix BioPharma Corp. (2007–2025)
The table below shows the annual total liabilities of Helix BioPharma Corp. from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | CA$3.22 Million ≈ $2.33 Million |
+103.67% |
| 2024-07-31 | CA$1.58 Million ≈ $1.14 Million |
-15.70% |
| 2023-07-31 | CA$1.87 Million ≈ $1.35 Million |
-45.09% |
| 2022-07-31 | CA$3.41 Million ≈ $2.47 Million |
-37.50% |
| 2021-07-31 | CA$5.46 Million ≈ $3.95 Million |
+183.53% |
| 2020-07-31 | CA$1.93 Million ≈ $1.39 Million |
-54.39% |
| 2019-07-31 | CA$4.22 Million ≈ $3.05 Million |
+57.85% |
| 2018-07-31 | CA$2.67 Million ≈ $1.93 Million |
+21.32% |
| 2017-07-31 | CA$2.20 Million ≈ $1.59 Million |
+69.02% |
| 2016-07-31 | CA$1.30 Million ≈ $943.29K |
+34.57% |
| 2015-07-31 | CA$969.00K ≈ $700.96K |
-7.01% |
| 2014-07-31 | CA$1.04 Million ≈ $753.77K |
+9.92% |
| 2013-07-31 | CA$948.00K ≈ $685.77K |
-31.90% |
| 2012-07-31 | CA$1.39 Million ≈ $1.01 Million |
-38.35% |
| 2011-07-31 | CA$2.26 Million ≈ $1.63 Million |
-4.04% |
| 2010-07-31 | CA$2.35 Million ≈ $1.70 Million |
+4.30% |
| 2009-07-31 | CA$2.26 Million ≈ $1.63 Million |
+97.20% |
| 2008-07-31 | CA$1.14 Million ≈ $827.55K |
-25.67% |
| 2007-07-31 | CA$1.54 Million ≈ $1.11 Million |
-- |
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more